NEW YORK (GenomeWeb) – Q-State Biosciences has closed a Series A financing worth an undisclosed amount and has merged with Pairnomix to create a company focused on precision medicine and drug discovery for central nervous system diseases.
Q-State, based in Cambridge, Massachusetts, has expertise in functional genomics, stem cell biology, gene editing, and machine-learning based bioinformatics. The company's Optopatch technology enables it to make physiological insights into personalized models of genetic nervous system conditions.
Meanwhile, Minneapolis-based Pairnomix offers genetic screening services for patients with rare diseases.
Q-State said that the new entity will offer comprehensive genomic services including sequencing, mutation modeling and screening, and targeted antisense oligonucleotide design for individuals through their physicians, as well as for larger underserved populations through drug-development partnerships with pharmaceutical companies.
The new company will remain headquartered in Cambridge and retain offices in Minneapolis. Matthew Fox, previously CEO of Pairnomix, will serve as CEO of the new company.
Early this year GenomeWeb reported that Q-State acquired the assets of Claritas Genomics for an undisclosed amount with plans to commercialize Claritas' clinical exome sequencing assays for precision medicine and drug discovery applications.